10-Q: CRISPR Therapeutics Reports Q3 Loss, Advances Gene Therapies

CRISPR Therapeutics reported an increased net loss in Q3 2025, driven by higher collaboration expenses, while highlighting positive Phase 1 data for CTX310 and ongoing commercialization of CASGEVY.

Summary

• Net loss for the three months ended September 30, 2025, increased to $106.4 million, compared to $85.9 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, increased to $451.0 million, compared to $328.9 million for the same period in 2024.
• Total revenue for the three months ended September 30, 2025, was $0.9 million, up from $0.6 million in 2024.
• Total revenue for the nine months ended September 30, 2025, was $2.6 million, up from $1.6 million in 2024.
• Research and development expenses decreased to $58.9 million for Q3 2025 from $82.2 million in Q3 2024, primarily due to decreased external R&D costs, employee-related expenses, and facility expenses.
• Collaboration expense, net, significantly increased to $57.1 million for Q3 2025 from $11.2 million in Q3 2024, mainly due to the absence of a deferral limit applicable in 2024 and increased CASGEVY commercial and manufacturing costs.
• Acquired in-process research and development expenses were $96.3 million for the nine months ended September 30, 2025, related to the Sirius Agreement, with no comparable expense in 2024.
• Cash, cash equivalents, and marketable securities totaled $1,944.1 million as of September 30, 2025.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $252.5 million, a significant increase from $92.7 million in 2024, primarily due to the timing of milestone payments from Vertex.
• The company issued 5.1 million common shares under its 2021 ATM program for $286.8 million in net proceeds during the nine months ended September 30, 2025.
• A new 2025 ATM program was initiated in October 2025, allowing for the sale of up to $600.0 million in common shares, with $11.7 million already raised.
• Positive Phase 1 data for CTX310, an in vivo gene-editing therapy for cardiovascular disease, showed dose-dependent reductions in ANGPTL3, triglycerides, and LDL, with a generally well-tolerated safety profile.
• CASGEVY, the first approved CRISPR-based therapy, continues to expand its global approvals and is being investigated in younger patient populations and long-term follow-up studies.

Sentiment

Score: 6

Explanation: While the company reported increased losses and higher cash burn, it also presented strong positive clinical data for CTX310 and continues to advance its approved product, CASGEVY, globally. The significant cash reserves provide a buffer, but the increased operating losses and the new government shutdown risk temper the overall sentiment. The strategic pipeline adjustments and new collaborations are positive for long-term potential.

Positives

• CASGEVY, the first CRISPR-based gene-editing therapy, has received approvals in the United States, European Union, Great Britain, Kingdom of Saudi Arabia, Kingdom of Bahrain, Qatar, Canada, Switzerland, and the United Arab Emirates for eligible patients 12 years and older with SCD or TDT.
• Efficacy data for CASGEVY supports its profile as a potential one-time functional cure for severe SCD and TDT.
• Positive Phase 1 data for CTX310 demonstrated dose-dependent, durable reductions in ANGPTL3 (mean -73%), triglycerides (mean -55%), and LDL (mean -49%) at the highest dose, with a well-tolerated safety profile.
• CTX310 is advancing into Phase 1b clinical trials, prioritizing development in severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.
• The company maintains a strong liquidity position with $1,944.1 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• The strategic collaboration with Sirius Therapeutics for siRNA therapies, including SRSD107, expands the company's pipeline into new modalities and disease areas (thrombosis).
• SRSD107 has completed two Phase 1 clinical trials, showing robust pharmacodynamic effects with sustained reductions in Factor XI levels and activity, and is now in a Phase 2 clinical trial.

Negatives

• Net loss increased significantly to $106.4 million for the three months ended September 30, 2025, from $85.9 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $451.0 million from $328.9 million in the prior year period.
• Collaboration expense, net, saw a substantial increase to $57.1 million in Q3 2025 from $11.2 million in Q3 2024, primarily due to the expiration of a cost deferral option and higher CASGEVY commercial and manufacturing costs.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $252.5 million, a considerable increase from $92.7 million in the prior year, indicating higher cash burn.
• The company strategically redirected resources away from the CTX131 CAR T program, despite encouraging Phase 1 data, to focus on other programs, indicating a pipeline prioritization decision that may leave some potential value unrealized.
• Other income, net, decreased by $14.1 million for the nine months ended September 30, 2025, primarily due to a decrease in interest income.

Risks

• Disruptions at the FDA, SEC, and other government agencies, such as the U.S. government shutdown beginning October 1, 2025, could hinder their ability to hire and retain key personnel, prevent new products from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions, negatively impacting business and timelines.
• Inadequate funding for government agencies, including from shutdowns, or other operational disruptions, may result in longer review times by the FDA, SEC, and other agencies, affecting regulatory submissions and approvals.
• The company has a history of recurring losses and expects to continue incurring losses for the foreseeable future, requiring additional capital to fund operations.
• The ability to generate revenue and achieve profitability depends significantly on successful development, regulatory approval, manufacturing, and commercialization of product candidates, which are uncertain.
• The trading prices for common shares and other biopharmaceutical companies have been highly volatile, potentially making it difficult to raise capital through equity sales on favorable terms.
• A recession, depression, or other sustained adverse market event, including geopolitical tensions, could materially and adversely affect the business and share value.
• The company is involved in lawsuits, investigations, and proceedings related to its intellectual property estate and commercial arrangements, the outcome of which is inherently uncertain and could adversely affect the business.
• A third-party licensor formally engaged with the company in Q2 2025 regarding intellectual property contracts, which may lead to additional amounts owed, with no estimable loss range currently provided.

Future Outlook

The company expects to continue incurring losses for the foreseeable future as it advances research and development programs, identifies new product candidates, conducts clinical trials, pursues business development, and expands manufacturing capabilities. Existing cash, cash equivalents, and marketable securities are expected to fund operating expenses and capital expenditures for at least the next 24 months. Additional financing opportunities will be considered when market terms are favorable to support long-term clinical development and future commercialization.

Management Comments

• Our mission is to create transformative gene-based medicines for serious human diseases.
• We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY, in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated.
• We believe that our innovative research, translational expertise, and clinical development experience, position us as a leader in the development of CRISPR-based therapeutics and may enable us to create an entirely new class of highly effective and potentially curative therapies for patients with both rare and common diseases for whom current biopharmaceutical approaches have had limited success.
• We believe CRISPR/Cas9 has the potential to create the next generation of CAR T cell therapies that may have a superior product profile and allow broader patient access compared to current autologous therapies.
• We recognize that we need to continue to innovate to unlock the full power of gene editing and bring potentially transformative therapies to even more patients.

Industry Context

CRISPR Therapeutics operates at the forefront of gene-editing technology, a rapidly evolving and high-potential segment of the biotechnology industry. The approval of CASGEVY marks a significant milestone, establishing the first CRISPR-based therapy globally and validating the platform. The company's pipeline, including CAR T, in vivo, and diabetes programs, reflects a broad application strategy, aligning with industry trends towards precision medicine and cell/gene therapies. The strategic redirection of resources from CTX131 to other programs indicates a focus on optimizing value creation in a competitive landscape. The collaboration with Sirius Therapeutics for siRNA therapies demonstrates an expansion beyond CRISPR/Cas9, leveraging complementary technologies to address unmet medical needs, particularly in cardiovascular and metabolic diseases, which are major areas of focus for pharmaceutical innovation.

Comparison to Industry Standards

• CASGEVY's approval as the first CRISPR-based gene-editing therapy sets a new industry benchmark for the speed of advancing gene-editing technology from discovery to market, demonstrating leadership in the field.
• The safety profile of CASGEVY, generally consistent with autologous stem cell transplant and myeloablative conditioning, aligns with expectations for such advanced therapies, similar to other approved gene therapies like Zynteglo (beti-cel) for beta-thalassemia or Skysona (elivaldogene autotemcel) for cerebral adrenoleukodystrophy, which also involve conditioning regimens.
• CTX310's Phase 1 data showing significant reductions in ANGPTL3, triglycerides, and LDL cholesterol positions it favorably against other lipid-lowering therapies, including PCSK9 inhibitors (e.g., Amgen's Repatha, Sanofi/Regeneron's Praluent) and emerging gene therapies for dyslipidemia, by offering a potential one-time treatment with durable effects.
• SRSD107's robust pharmacodynamic effects, including over 93% reduction in Factor XI levels and activity, and sustained responses for up to six months, suggest a differentiated profile compared to existing Factor Xa inhibitors (e.g., rivaroxaban, apixaban) and other anti-Factor XI modalities, particularly regarding bleeding risk and potential for reversibility.

Legal Proceedings

• In the ordinary course of business, the company is involved in lawsuits, investigations, proceedings, and threats of litigation related to intellectual property and commercial arrangements, including inter partes administrative proceedings in patent offices.
• A third-party licensor formally engaged with the company in Q2 2025 regarding certain matters under their intellectual property contracts that may lead to further actions and additional amounts being owed by the company, with no estimable loss or range of loss currently provided.

Related Party Transactions

• Collaboration agreements with Vertex Pharmaceuticals Incorporated for hemoglobinopathies (CASGEVY) and diabetes programs, involving cost sharing, milestone payments, and royalties.
• Letter Agreement with Vertex regarding the priority review voucher for CASGEVY, with potential payments to the company of $43.0 million or 42% of net proceeds upon utilization or transfer.
• Collaboration, option, and license agreement with Sirius Therapeutics, involving an upfront cash payment of $25.0 million and issuance of 1,842,105 common shares (approximately $70.0 million), with equal sharing of development and commercialization costs and potential future milestones and royalties.

Stakeholder Impact

• Shareholders face potential dilution from ongoing at-the-market equity offerings (2021 ATM and 2025 ATM) but benefit from a strong cash position and promising pipeline developments.
• Patients with severe SCD, TDT, cardiovascular diseases, and thrombosis may benefit from the continued development and commercialization of CASGEVY, CTX310, and SRSD107, offering potential new treatment options.
• Employees may experience continued headcount adjustments, as indicated by decreased employee-related expenses, but are involved in advancing a leading gene-editing platform and pipeline.
• Regulatory bodies (FDA, SEC) are impacted by government shutdowns, which could in turn affect the company's ability to obtain timely approvals for its product candidates.

Next Steps

• Continue to investigate CASGEVY in clinical trials for patients 5 to 11 years of age with severe SCD and TDT.
• Conduct long-term follow-up clinical trials for CASGEVY participants for up to 15 years after infusion.
• Advance the internally developed targeted conditioning program and in vivo hematopoietic stem cell editing approaches through preclinical studies.
• Advance CTX112, the next-generation allogeneic CAR T program targeting CD19, in ongoing clinical trials for hematologic malignancies and autoimmune indications.
• Advance CTX310 into Phase 1b clinical trials, prioritizing development in severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.
• Continue to advance earlier stage in vivo programs (CTX340, CTX450, CTX460) through preclinical studies and IND/CTA-enabling studies.
• Continue the Phase 2 clinical trial evaluating SRSD107 for preventing VTE following total knee arthroplasty.
• Continue development of CTX211 in a Phase 1 clinical trial for Type 1 Diabetes.
• Further develop CRISPR-X technologies for next-generation editing modalities, including whole gene correction and insertion via non-viral DNA delivery and all-RNA systems.
• Monitor developments and assess the impact of the One Big Beautiful Bill Act on deferred tax assets, effective tax rate, and long-term tax planning strategies.
• Continue to consider opportunities to raise additional funds through equity or debt financings to support long-term clinical development and future commercialization.

Key Dates

Recommendation

CRISPR Therapeutics presents a mixed financial picture with increased net losses and higher operating cash burn, which are significant concerns. However, these are offset by a robust cash position of nearly $2 billion, providing substantial runway. The positive Phase 1 data for CTX310 is a strong catalyst, demonstrating the potential of its in vivo gene-editing platform beyond CASGEVY. The continued global rollout and investigation of CASGEVY, the first approved CRISPR therapy, further validates the company's core technology. The strategic pipeline adjustments and new collaborations are prudent for long-term value. The updated risk of a U.S. government shutdown introduces regulatory uncertainty. Given the strong pipeline progress and cash reserves balanced against ongoing losses and external risks, a 'hold' recommendation is appropriate for investors to monitor execution and further clinical developments.

Keywords

CRISPR, Gene Editing, CASGEVY, Exa-cel, Sickle Cell Disease, Beta Thalassemia, CAR T, CTX310, ANGPTL3, Cardiovascular Disease, SRSD107, Factor XI, Thrombosis, Type 1 Diabetes, CTX211, Biotechnology, Pharmaceuticals, Clinical Trials, SEC Filing, 10-Q